147 related articles for article (PubMed ID: 37060904)
21. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
[TBL] [Abstract][Full Text] [Related]
22. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
23. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
[TBL] [Abstract][Full Text] [Related]
24. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of
Tang TT; Konradi AW; Feng Y; Peng X; Ma M; Li J; Yu FX; Guan KL; Post L
Mol Cancer Ther; 2021 Jun; 20(6):986-998. PubMed ID: 33850002
[TBL] [Abstract][Full Text] [Related]
25. Emerging roles of TEAD transcription factors and its coactivators in cancers.
Pobbati AV; Hong W
Cancer Biol Ther; 2013 May; 14(5):390-8. PubMed ID: 23380592
[TBL] [Abstract][Full Text] [Related]
26. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.
Bokhovchuk F; Mesrouze Y; Izaac A; Meyerhofer M; Zimmermann C; Fontana P; Schmelzle T; Erdmann D; Furet P; Kallen J; Chène P
FEBS J; 2019 Jun; 286(12):2381-2398. PubMed ID: 30903741
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells.
Sun Y; Hu L; Tao Z; Jarugumilli GK; Erb H; Singh A; Li Q; Cotton JL; Greninger P; Egan RK; Tony Ip Y; Benes CH; Che J; Mao J; Wu X
Nat Commun; 2022 Nov; 13(1):6744. PubMed ID: 36347861
[TBL] [Abstract][Full Text] [Related]
28. A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities.
Lou J; Lu Y; Cheng J; Zhou F; Yan Z; Zhang D; Meng X; Zhao Y
Eur J Med Chem; 2022 Dec; 243():114684. PubMed ID: 36063664
[TBL] [Abstract][Full Text] [Related]
29. Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity.
Gridnev A; Maity S; Misra JR
Front Oncol; 2022; 12():1021823. PubMed ID: 36523977
[TBL] [Abstract][Full Text] [Related]
30. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
31. YAP/TAZ-TEAD is a novel transcriptional regulator of genes encoding steroidogenic enzymes in rat granulosa cells and KGN cells.
Mizutani T; Orisaka M; Kawabe S; Morichika R; Uesaka M; Yoshida Y
Mol Cell Endocrinol; 2023 Jan; 559():111808. PubMed ID: 36309205
[TBL] [Abstract][Full Text] [Related]
32. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
33. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
Pobbati AV; Rubin BP
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors.
Holden JK; Cunningham CN
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29558384
[TBL] [Abstract][Full Text] [Related]
35. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
[TBL] [Abstract][Full Text] [Related]
36. Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.
Holden JK; Crawford JJ; Noland CL; Schmidt S; Zbieg JR; Lacap JA; Zang R; Miller GM; Zhang Y; Beroza P; Reja R; Lee W; Tom JYK; Fong R; Steffek M; Clausen S; Hagenbeek TJ; Hu T; Zhou Z; Shen HC; Cunningham CN
Cell Rep; 2020 Jun; 31(12):107809. PubMed ID: 32579935
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and Structural Characterization of a Peptidic Inhibitor of the YAP:TEAD Interaction That Binds to the α-Helix Pocket on TEAD.
Mesrouze Y; Gubler H; Villard F; Boesch R; Ottl J; Kallen J; Reid PC; Scheufler C; Marzinzik AL; Chène P
ACS Chem Biol; 2023 Mar; 18(3):643-651. PubMed ID: 36825662
[TBL] [Abstract][Full Text] [Related]
38. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis.
Zhou Y; Huang T; Cheng AS; Yu J; Kang W; To KF
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805820
[TBL] [Abstract][Full Text] [Related]
39. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
[TBL] [Abstract][Full Text] [Related]
40. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
